title: Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.
abstract: The intent of this study was to evaluate the safety and efficacy of high-activity 111In-pentetreotide in patients with neuroendocrine tumors. Thirty-two patients with pentetreotide-avid neuroendocrine tumors received therapy from August 2005 to November 2006. Fourteen (14) patients received 1 treatment and 18 patients received 2 treatments. Patients were followed an average of 12.73 months (range 1.2-24.5). Seventeen (17) patients (53%) had grade I or II hematologic toxicities, and 1 patient had grade III thrombocytopenia. One patient had grade II liver toxicity, which appeared 4 weeks after therapy and resolved on week 5. No patient had renal toxicity. Of the patients who completed 2 treatment cycles, 2 of 18 patients had partial disease regression, and 16 of 18 patients with previously progressive disseminated neuroendocrine disease achieved stable disease by imaging criteria. A decrease in serum tumor markers was observed in 14 of 18 patients given 2 therapies. A clinical response was achieved in 84% of the patients. Upon interim analysis, median survival was approximately 13 months (range 1.2-24.5). These results show that high-activity 111In-pentetreotide therapy is effective in patients with progressive disseminated neuroendocrine tumors.
authors.affiliation: Excel Diagnostics Imaging Clinics, Houston, TX 77042, USA. edelpassand@exceldiagnostics.com
authors.forename: Ebrahim S
authors.initials: ES
authors.lastname: Delpassand
authors.forename: Jennifer
authors.initials: J
authors.lastname: Sims-Mourtada
authors.forename: Hitomi
authors.initials: H
authors.lastname: Saso
authors.forename: Ali
authors.initials: A
authors.lastname: Azhdarinia
authors.forename: Faramarz
authors.initials: F
authors.lastname: Ashoori
authors.forename: Farzad
authors.initials: F
authors.lastname: Torabi
authors.forename: Gregory
authors.initials: G
authors.lastname: Espenan
authors.forename: Warren H
authors.initials: WH
authors.lastname: Moore
authors.forename: Eugene
authors.initials: E
authors.lastname: Woltering
authors.forename: Lowell
authors.initials: L
authors.lastname: Anthony
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D012044:Regression Analysis; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007205:Indium Radioisotopes; D013004:Somatostatin; C081788:pentetreotide